Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Recurrence. Found 18 abstracts

Nejati R, Wei S, Uzzo RG, Poureghbali S, Pei J, Talarchek JN, Ruth K, Dulaimi E, Kutikov A, Testa JR, Al-Saleem T. Monosomy of Chromosome 9 Is Associated With Higher Grade, Advanced Stage, and Adverse Outcome in Clear-cell Renal Cell Carcinoma. Clin Genitourin Cancer. 2020 Sep 26;18(1):56-61.
Epperla N, Maddocks KJ, Salhab M, Chavez JC, Reddy N, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn M, Calzada O, Xavier AC, Zhou Z, Hossain NM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Barta SK, Chhabra S, Lansigan F, Mehta A, Jaglal MV, Evans A, Flowers CR, Cohen JB, Fenske TS, Hamadani M, Costa LJ. C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy. Cancer. 2017 Nov 15;123(22):4411-8.
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, D'Amico TA, Decamp MM, Dilling TJ, Dobelbower M, Doebele RC, Govindan R, Gubens MA, Hennon M, Horn L, Komaki R, Lackner RP, Lanuti M, Leal TA, Leisch LJ, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network. 2017 Apr;15(4):504-35.
Zahid MF, Khan N, Hashmi SK, Kizilbash SH, Barta SK. Central nervous system prophylaxis in diffuse large B-cell lymphoma. Eur J Haematol. 2016 Aug;97(2):108-20.
Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. The New England journal of medicine. 2015 Jan 22;372(4):311-9.   PMCID: 4348009
Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C, Kaufman JL, Lentzsch S, Vogl DT, Gomes CL, Pascucci N, Smith DD, Orlowski RZ, Durie BG. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood. 2015 Nov 12;126(20):2284-90.   PMCID: PMC4643003
Barr PM, Miller TP, Friedberg JW, Peterson DR, Baran AM, Herr M, Spier CM, Cui H, Roe DJ, Persky DO, Casulo C, Littleton J, Schwartz M, Puvvada S, Landowski TH, Rimsza LM, Dorr RT, Fisher RI, Bernstein SH, Briehl MM. Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma. Blood. 2014 Aug 21;124(8):1259-65.   PMCID: Pmc4141515
Ma CM, Luxton G, Orton CG. Point/counterpoint: pulsed reduced dose rate radiation therapy is likely to become the treatment modality of choice for recurrent cancers. Med Phys. 2011 Sep;38(9):4909-11.   PMCID: not NIH funded
Plimack ER, Tannir N, Lin E, Bekele BN, Jonasch E. Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measures. Cancer. 2009 May;115(9):1859-66.
Bleicher RJ, Topham NS, Morrow M. Beauty and the beast: management of breast cancer after plastic surgery. Ann Surg. 2008 Apr;247(4):680-6.
Burtness BA, Manola J, Axelrod R, Argiris A, Forastiere AA. A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. Ann Oncol. 2008 May;19(5):977-83.
Henry LR, Sigurdson E, Ross E, Hoffman JP. Hydronephrosis does not preclude curative resection of pelvic recurrences after colorectal surgery. Annals of Surgical Oncology. 2005 Jan;12(10):786-92.
Laport GG, Levine BL, Stadtmauer EA, Schuster SJ, Luger SM, Grupp S, Bunin N, Strobl FJ, Cotte J, Zheng Z, Gregson B, Rivers P, Vonderheide RH, Liebowitz DN, Porter DL, June CH. Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood. 2003 Sep 15;102(6):2004-13.
Held-Warmkessel J. Treatment of advanced prostate cancer. Semin Oncol Nurs. 2001 May;17(2):118-28.
Langer CJ. Staging and prognosis in lung cancer: making the complex accessible. Cancer Treat Res. 2001 Jan;105:53-94.
Bookman MA. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. The oncologist. 1999 Jan;4(2):87-94.
Movsas B, Barrows MC, Steinberg SM, Middleton LP, Okunieff P, Jaffe ES, Epstein AH. Response during radiotherapy may be associated with outcome in mediastinal Hodgkin's disease. Radiat Oncol Investig. 1998 Jan;6(5):216-25.
Ozols RF. Update of the NCCN ovarian cancer practice guidelines. Oncology (Huntingt). 1997 Nov;11(11A):95-105.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Recurrence

Recurrence Female Male therapeutic use therapy drug therapy pathology adverse effects Antineoplastic Combined Chemotherapy Protocols Adult Middle Aged Human mortality administration & dosage Treatment Outcome Aged Disease-Free Survival Combined Modality Therapy Disease Progression Salvage Therapy diagnosis Prognosis Neoplasm Drug Resistance Neoplasm Metastasis chemically induced epidemiology Squamous Cell Carcinoma Survival Analysis Follow-Up Studies Neoplasm Proteins Middle Age Immunotherapy genetics 80 and over Aged drug effects adverse Remission Induction Time Factors methods Local Neoplasm Recurrence Survival Rate Radiotherapy Clinical Trials effects Retrospective Studies Lung Neoplasms Adolescent metabolism prevention & control Antineoplastic Agents Hodgkin Disease radiotherapy Hematopoietic Stem Cell Transplantation Large B-Cell Lymphoma-Diffuse Ovarian Neoplasms Adjuvant Chemotherapy Topotecan classification basic helix-loop-helix (MYC) Pulmonary Embolism Angiogenesis Inhibitors Maximum Tolerated Dose central nervous system involvement Pneumonectomy Reed-Sternberg Cells radiography Superoxide Dismutase Breast Neoplasms non-Hodgkin lymphoma Dose Fractionation transplantation central nervous system prophylaxis Chromosome 9 Salvage Non-Small-Cell Lung Carcinoma Clinical Trials as Topic Spinal Injections Oxidative Stress Taxoids Incidence dosage Renal cell carcinoma Peripheral Nervous System Diseases Prostatic Neoplasms Young Adult Diagnostic Imaging Paclitaxel etiology Oligopeptides biosynthesis myc Genes Radiotherapy Dosage physiopathology Neoplastic Gene Expression Regulation Lung Adenocarcinoma Practice Guidelines Colorectal cancer Antineoplastic Antibiotics Kidney Neoplasms hematopoietic cell transplantation (HCT) Non-Small-Cell Carcinoma Predictive Value of Tests Cytarabine T-Lymphocytes Rituximab Mammaplasty immunology Androgen Antagonists diffuse large B-cell lymphoma (DLBCL) administration & diffuse large B-cell lymphoma CD34 Antigens Biomarkers Non-US Gov't Support Hematologic Diseases Physical Examination Oncologic Nursing Oxidants Carmustine Interferon-alpha Central Nervous System Neoplasms Molecular Targeted Therapy chemistry Risk Factors Epothilones Glutathione Peroxidase Hexanones Biological Tumor Markers Breast Implants secondary Lymphatic Metastasis Telomerase Genetic Translocation MYC proto-oncogene Hematopoietic Stem Cells Disease Management Programmed Cell Death 1 Receptor Etoposide Neoplasm Staging Large Cell Carcinoma Immunoconjugates antagonists & inhibitors Factual Databases Mediastinum Adjuvant Radiotherapy Outcome Assessment (Health Care) Cyclophosphamide Non-Hodgkin Lymphoma
Last updated on Thursday, April 02, 2020